Post-operative cataract patients treated with Loteprednol etabonate as a gel or vehicle four times a day for two weeks saw significant reduction in pain and inflammation, according to a study published in the Journal of Cataract & Refractive Surgery.
The double-masked parallel-group study of 406 patients with anterior chamber cell grade two or higher at 17 U.S. sites showed 30.5 percent of gel-treated patients and 16.3 percent in the vehicle group had completely recovered from ACC by day eight. By the same time, nearly three-quarters of the first group and 41.9 percent of the second had grade 0 pain. No discomfort on drop instillation was reported by 85 percent of patients.
Houston Ophthalmologists Named 'Best Doctors'
Reduced-Fluence Laser Therapy For PCV Patients Improves, Maintains Visual Acuity in 2-Year Follow-Up Study
The double-masked parallel-group study of 406 patients with anterior chamber cell grade two or higher at 17 U.S. sites showed 30.5 percent of gel-treated patients and 16.3 percent in the vehicle group had completely recovered from ACC by day eight. By the same time, nearly three-quarters of the first group and 41.9 percent of the second had grade 0 pain. No discomfort on drop instillation was reported by 85 percent of patients.
More Articles on Ophthalmology:
San Antonio Eye Center Adds New OfficeHouston Ophthalmologists Named 'Best Doctors'
Reduced-Fluence Laser Therapy For PCV Patients Improves, Maintains Visual Acuity in 2-Year Follow-Up Study